Drug Search Results
More Filters [+]

Polaprezinc

Alternative Names: polaprezinc
Latest Update: 2023-09-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HO1 Inducer

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | China | Korea

Approved Indications: None

Known Adverse Events: None

Company: ZERIA
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Polaprezinc

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Taste Disorders

Phase 2: Liver Cancer|Colorectal Cancer|Mucositis|Intestinal Diseases|Lymphoma|Leukemia|Digestive System Cancer|Mouth Cancer|Gastrointestinal Cancer|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2300070469

N/A

Not yet recruiting

Helicobacter Infections

2024-02-29

PEACe

P2

Completed

Prostate Cancer

2023-01-20

ChiCTR1900028329

N/A

Recruiting

Unknown

2022-12-31

ToPaZ Study

P2

Completed

Digestive System Cancer|Colorectal Cancer|Mucositis|Gastrointestinal Cancer|Mouth Cancer|Intestinal Diseases|Lymphoma|Leukemia|Liver Cancer

2022-07-01

Recent News Events